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Abstract 
Background: Risk stratification of cardiovascular events in patients with type 2 diabetes mellitus (T2DM) has not 
been established. Coronary artery calcium score (CACS) and non-alcoholic fatty liver disease (NAFLD) are indepen-
dently associated with cardiovascular events in T2DM patients. This study examined the incremental prognostic value 
of NAFLD assessed by non-enhanced computed tomography (CT) in addition to CACS and Framingham risk score 
(FRS) for cardiovascular events in T2DM patients.
Methods: This prospective pilot study included 529 T2DM outpatients with no history of cardiovascular disease who 
underwent CACS measurement because of suspected coronary artery disease. NAFLD was defined on CT images as 
a liver:spleen attenuation ratio < 1.0. Cardiovascular events were defined as cardiovascular death, nonfatal myocardial 
infarction, late coronary revascularization, nonfatal stroke, or hospitalization for heart failure.
Results: Among 529 patients (61% men, mean age 65 years), NAFLD was identified in 143 (27%). Forty-four cardio-
vascular events were documented during a median follow-up of 4.4 years. In multivariate Cox regression analysis, 
NAFLD, CACS, and FRS were associated with cardiovascular events (hazard ratios and 95% confidence intervals 5.43, 
2.82–10.44, p < 0.001; 1.56, 1.32–1.86, p < 0.001; 1.23, 1.08–1.39, p = 0.001, respectively). The global χ2 score for pre-
dicting cardiovascular events increased significantly from 27.0 to 49.7 by adding NAFLD to CACS and FRS (p < 0.001). 
The addition of NAFLD to a model including CACS and FRS significantly increased the C-statistic from 0.71 to 0.80 
(p = 0.005). The net reclassification achieved by adding CACS and FRS was 0.551 (p < 0.001).
Conclusions: NAFLD assessed by CT, in addition to CACS and FRS, could be useful for identifying T2DM patients at 
higher risk of cardiovascular events.
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Background
The prevalence of type 2 diabetes mellitus (T2DM) 
has been increasing rapidly worldwide [1]. T2DM is 
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cardiovascular events compared with non-T2DM sub-
jects [2, 3]. The prevention of cardiovascular events 
in T2DM patients has thus become a major concern. 
Although several clinical risk scores for predicting car-
diovascular events have been proposed, there is currently 
no widely used risk stratification for T2DM patients. Pre-
vious studies showed that coronary artery calcium score 
(CACS) determined by coronary computed tomography 
(CT) provided additional information on cardiovascular 
events in T2DM patients beyond that provided by the 
commonly used Framingham risk score (FRS) [4, 5]. The 
latest American Heart Association and American College 
of Cardiology (AHA/ACC) guidelines for the primary 
prevention of atherosclerotic cardiovascular disease 
allowed the use of CACS in intermediate-risk patients 
if the risk level was uncertain [6]. Thus, CACS could be 
a useful factor for determining cardiovascular risk in 
patients with T2DM.
Growing evidence suggests that non-alcoholic fatty 
liver disease (NAFLD) is associated with cardiovascu-
lar events independently of established cardiovascular 
risk factors [7–9]. NAFLD is a frequent comorbidity of 
metabolic syndrome and T2DM [10]. Previous stud-
ies showed that metabolic syndrome and T2DM might 
be predictors of vascular damage [11, 12], and complex 
and bidirectional associations have been demonstrated 
between NAFLD and metabolic syndrome and T2DM 
[13]. We recently reported on the prognostic value of 
NAFLD assessed by non-enhanced CT in patients with 
suspected coronary artery disease who underwent cor-
onary CT angiography [14], highlighting the benefits 
of concomitant assessment of liver fat content during 
the acquisition of coronary CT angiography to detect 
patients at higher risk of cardiovascular events.
We therefore hypothesized that the assessment of 
NAFLD using non-enhanced CT, in addition to CACS 
and FRS, might improve risk stratification for cardiovas-
cular events in T2DM patients. We tested this hypoth-
esis in a cohort of patients with suspected coronary 
artery disease who underwent CACS measurement, with 
the aim of evaluating the additional prognostic value 
of NAFLD compared with CACS and FRS in T2DM 
patients.
Methods
Study population and data collection
  Patient enrollment in this study is shown in Fig. 1. This 
prospective study enrolled 529 Japanese outpatients 
with T2DM from August 2011 to December 2016. The 
patients had no history of cardiovascular disease but had 
been referred to our hospital with suspected coronary 
artery disease. CACS was measured in 172 asymptomatic 
patients for risk stratification by evaluating coronary 
atherosclerosis, and in the remaining 357 patients with 
atypical symptoms [n = 44] or no symptoms [n = 313] 
because of abnormalities in rest or stress electrocardio-
grams. No patients had any history of cardiovascular dis-
eases, including coronary artery disease, heart failure, or 
cerebrovascular disease. Patients were excluded if they 
consumed > 20 g of alcohol per day, had known liver dis-
ease, were using oral corticosteroids or amiodarone, or 
had a coexisting active tumor. All the patients underwent 
Fig. 1 Flowchart of study design. CACS coronary artery calcium score, T2DM type 2 diabetes mellitus, NAFLD non-alcoholic fatty liver disease
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blood tests, measurement of CACS, and abdominal CT 
on the same day.
Assessment of coronary calcification
CT imaging was performed using a Somatom Defini-
tion Flash scanner (Siemens Medical Solutions, Erlan-
gen, Germany). CACS was measured using the following 
parameters: 120 kV, 150 mA, and 3-mm thickness. CACS 
was calculated using an automated computerized sys-
tem (Virtual Place, Raijin; AZE Inc., Tokyo, Japan) and 
the Agatston method, which involved multiplying the 
area of each calcified plaque by a density factor deter-
mined by the peak pixel intensity within the plaque. 
The plaque-specific scores for all the slices were added 
together. The density factor was 1, 2, 3, or 4 for plaques 
with peak intensities of 130–199, 200–299, 300–399, and 
≥ 400 Hounsfield units (HU), respectively [15]. In addi-
tion, patients were divided into three groups according to 
CACS: CACS 0, CACS (1–99), and CACS (≥ 100).
Assessment of visceral adipose tissue and NAFLD
Abdominal non-contrast CT scans were carried out 
alongside cardiac CT, at a level including the liver, spleen, 
and umbilicus. The visceral adipose tissue area was 
assessed using a semi-automatic segmentation technique 
at the umbilical level [16]. Hepatic and splenic Hounsfield 
attenuations were measured using the maximum circular 
regions of interest in the liver and spleen (at least 1 cm2) 
[17]. Regions of interests in the liver were located at two 
segments (right anterior and right posterior) by avoiding 
the inclusion of large vessels or biliary structures [17]. 
The liver:spleen attenuation ratio was calculated using 
the mean HU measurement of the two right liver lobe 
regions of interest. In this study, we defined hepatic stea-
tosis as a liver:spleen attenuation ratio < 1.0 [18]. NAFLD 
was finally diagnosed after other causes of hepatic steato-
sis were ruled out.
Assessment of other risk factors
Hypertension was defined as a seated blood pres-
sure > 140/90  mmHg or current treatment with antihy-
pertensive medication. Dyslipidemia was defined as one 
or more of the following: serum triglycerides ≥ 150  mg/
dL, high-density lipoprotein cholesterol < 40 mg/dL, low-
density lipoprotein cholesterol ≥ 140  mg/dL, or current 
treatment with a lipid-lowering drug. Smoking status 
was defined as currently smoking or not smoking. Obe-
sity was defined as a body mass index ≥ 25  kg/m2. FRS 
was calculated according to the algorithm presented by 
Wilson et  al. to estimate the 10-year risk of a coronary 
heart disease event [19]. In addition, patients were classi-
fied into three groups according to the European Society 
of Cardiology recommendations as very-high, high, or 
moderate risk [20].
Outcomes and follow‑up
The patients were followed up prospectively from the 
date of CT. Clinical follow-up information was obtained 
by review of medical records or telephone interviews by 
attending physicians. The study endpoint was cardiovas-
cular events defined as cardiovascular death, nonfatal 
myocardial infarction, late coronary revascularization, 
nonfatal stroke, or hospitalization due to heart failure. 
The diagnosis of myocardial infarction was based on 
the criteria of typical acute chest pain and persistent 
ST-segment elevation or positive cardiac enzymes. Late 
coronary revascularization was defined as percutaneous 
coronary intervention or coronary artery bypass grafting 
as indicated by the treating physician due to stable angina 
with a newly positive functional test. Patients with sched-
uled revascularization within 90 days of the CACS meas-
urement were not counted as events and were censored 
at the time of first revascularization. Hospitalization for 
heart failure was defined as any unplanned stay overnight 
or longer in a hospital environment, for which heart 
failure was the principal reason for admission. Nonfatal 
stroke was defined as sudden-onset non-convulsive and 
focal neurological deficit persisting for > 24 h.
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation or median with interquartile range. Dichoto-
mous variables were expressed as number and percent-
age. Differences in continuous variables between two 
groups were analyzed by Student’s t-test or Mann–Whit-
ney U-test, as appropriate. Categorical data were com-
pared by χ2 tests. In subsequent analysis, triglyceride data 
were log-transformed because they did not show a nor-
mal distribution. Similarly, the distribution of Agatston 
score data was also highly skewed, and CACS was there-
fore log-transformed after adding 1 to all calcium scores 
to manage values of 0 (log[CACS + 1]). Kaplan–Meier 
curves were used to estimate cumulative rates of car-
diovascular events. Differences between time-to-event 
curves were compared by log-rank tests. Annual event 
rates were calculated by dividing the 4-year Kaplan–
Meier event rates by 4 and comparing them. The effects 
of variables on cardiovascular events were analyzed by 
Cox proportional hazard analysis, and the results were 
reported as hazard ratios (HR) with 95% confidence 
intervals (CI). The incremental value of NAFLD was 
assessed by global χ2 tests and receiver operating charac-
teristic (ROC) curve analysis. C-statistics were calculated 
from the ROC curves and compared using the Delong 
test. The category-free net reclassification improvement 
Page 4 of 10Ichikawa et al. Cardiovasc Diabetol            (2021) 20:8 
was also calculated. All reported p values were two-sided 
and p < 0.05 was considered statistically significant. Sta-
tistical analyses were performed using SPSS statistical 
software (version 24; IBM Corp., Armonk, NY, USA) and 
the R statistical package (version 3.5.2; R Foundation for 
Statistical Computing, Vienna, Austria).
Results
Patient characteristics
The mean age of the study population was 65 years, 324 
(61%) patients were men, and the median CACS was 63. 
Overall, 143 (27%) patients had CT evidence of NAFLD. 
The baseline characteristics of patients with and without 
NAFLD are shown in Table 1. Patients with NAFLD were 
younger (p < 0.001) and had a higher body mass index 
(p < 0.001) and visceral adipose tissue area (p < 0.001), and 
higher prevalences of dyslipidemia (p = 0.021) and obe-
sity (p < 0.001) compared with patients without NAFLD. 
The proportion of very-high-risk patients was greater in 
patients with NAFLD than in patients without NAFLD 
(p = 0.003). Oral anti-hyperglycemic drugs were more 
frequent among patients with NAFLD. Patients with 
NAFLD also had higher levels of liver enzymes (p < 0.001) 
and triglycerides (p < 0.001), and lower levels of high-den-
sity lipoprotein cholesterol (p < 0.001). There was a sig-
nificant difference in CACS between the two groups with 
Table 1 Patient characteristics according to presence or absence of NAFLD
Data presented as mean ± standard deviation, number (%), or median [25th–75th percentile]
NAFLD non-alcoholic fatty liver disease, ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, eGFR estimated glomerular filtration rate, 
AST aspartate aminotransferase, ALT alanine aminotransferase ratio, LDL low-density lipoprotein, HDL-C high-density lipoprotein, HbA1c glycated hemoglobin A1c, 
CACS coronary artery calcium score, FRS Framingham risk score, ESC European Society of Cardiology, DPP4 dipeptidyl peptidase-4
Variables NAFLD, n = 143 No NAFLD, n = 386 p value
Age, years 60 ± 12 67 ± 12 < 0.001
Male gender 90 (63) 234 (61) 0.627
Body mass index, kg/m2 28 ± 4 24 ± 4 < 0.001
Visceral adipose tissue,  cm2 139 ± 55 102 ± 57 < 0.001
Hypertension 108 (76) 265 (69) 0.124
Dyslipidemia 98 (69) 222 (58) 0.021
Current smoker 40 (28) 86 (22) 0.172
Obesity 99 (69) 126 (33) < 0.001
β blocker 29 (20) 80 (21) 0.91
Calcium channel blocker 55 (39) 157 (41) 0.645
ACE-I or ARB 80 (56) 192 (50) 0.205
Statin 71 (50) 165 (43) 0.156
Insulin therapy 17 (12) 33 (9) 0.244
Oral antihyperglycemic drugs 94 (66) 198 (51) 0.003
Metformin 46 (32) 54 (14) < 0.001
Thiazolidinediones 31 (22) 101 (26) 0.289
Alpha glucosidase inhibitor 20 (14) 62 (16) 0.558
DPP4 inhibitors 57 (40) 117 (30) 0.038
Creatinine, mg/dL 0.93 ± 0.91 1.14 ± 1.40 0.046
eGFR, mL/min/1.73  m2 72 ± 19 64 ± 23 < 0.001
AST, IU/L 29 ± 15 22 ± 13 < 0.001
ALT, IU/L 35 ± 22 22 ± 23 < 0.001
Total cholesterol, mg/dL 183 ± 37 183 ± 35 0.911
LDL cholesterol, mg/dL 108 ± 32 109 ± 30 0.767
HDL cholesterol, mg/dL 49 ± 16 56 ± 16 < 0.001
Triglyceride, mg/dL 150(102, 235) 109(81, 156) < 0.001
HbA1c, % 7.6 ± 1.6 7.3 ± 1.7 0.076
CACS 30(0, 186) 107 (0, 536) 0.002
CACS category (0–99/≥100) 41/52/50 97/90/199 0.001
FRS 8.6 ± 3.9 8.6 ± 3.8 0.796
ESC very-high risk group 110 (77) 245 (64) 0.003
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higher CACS among non-NAFLD patients (p = 0.002). 
The mean dose-length product for abdominal CT was 
251  mGy  cm, and the effective dose for each imaging 
modality was 3.77 mSv, using a conversion coefficient of 
0.015.
Outcome data
Forty-six patients (11 NAFLD, 35 non-NAFLD) with 
scheduled revascularization within 90  days of the index 
CT were censored at the time of revascularization. Forty-
four cardiovascular events were documented during 
a median follow-up of 4.4  years (23 events in NAFLD 
patients: 1 cardiovascular death, 5 stroke, 5 myocar-
dial infarction, 10 late revascularization, 2 heart failure; 
21 events in non-NAFLD patients: 3 stroke, 7 myocar-
dial infarction, 8 late revascularization, 3 heart failure). 
Kaplan–Meier curves showed the cumulative event-free 
survivals for cardiovascular events in patients stratified 
by CACS (0, 1–100 or ≥ 100), with or without NAFLD. 
The annual cardiovascular event rate in patients with 
NAFLD was significantly higher than that in patients 
without NAFLD (2.95% vs. 0.98%; p < 0.001) (Fig. 2a). In 
Fig. 2 Kaplan–Meier curves showing cumulative incidence of cardiovascular events. Kaplan–Meier curves of cardiovascular events presented 
according to a presence or absence of NAFLD, and b–d presence or absence of NAFLD according to CACS categories. a All patietnts. b Patients 
wigh CACS 0. c Patients with CACS 1–99. d Patients with CACS ≥ 100. CACS coronary artery calcium score, NAFLD non-alcoholic fatty liver disease
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addition, patients were divided into three groups accord-
ing CACS and compared in relation to the presence or 
absence of NAFLD (Fig.  2b–d). Patients with NAFLD 
and CACS ≥ 100 had a significantly higher incidence 
of cardiovascular events. The annual rates of cardiovas-
cular events in patients with CACS 0 with and without 
NAFLD were very low and similar in both groups (0.00% 
vs. 0.30%; p = 0.513) (Fig. 2b). The annual rates of cardio-
vascular events in patients with CACS 1–99 and ≥ 100 
were significantly higher in NAFLD compared with 
non-NAFLD patients (2.25% vs. 0.33%; p = 0.024, Fig. 2c; 
and 6.40% vs. 1.78%; p < 0.001, Fig.  2d, respectively). As 
shown in Table  2, univariate Cox regression analysis 
identified presence of NAFLD, CACS, and FRS as factors 
associated with cardiovascular events. Furthermore, mul-
tivariate Cox regression analysis identified the presence 
of NAFLD, CACS, and FRS as associated with cardio-
vascular events (HR, 95% CI 5.43, 2.82–10.44, p < 0.001; 
1.56, 1.32–1.86, p < 0.001; 1.23, 1.08–1.39, p = 0.001, 
respectively).
Comparison of predictive performances for cardiovascular 
events
We investigated the incremental value of adding NAFLD 
compared with CACS and FRS alone for predicting car-
diovascular events. The global χ2 score and ROC curve 
analysis were calculated to assess the incremental predic-
tive value of NAFLD. Adding NAFLD to log (CACS + 1) 
and FRS significantly increased the global χ2 score from 
27.0 to 49.7 (p < 0.001) (Fig. 3a). The results of ROC analy-
sis comparing the area under the curve for each group are 
shown in Fig. 3b. Adding NAFLD significantly increased 
the C-statistic of Model 1 (FRS + log [CACS + 1]) from 
0.71 to 0.80 (p = 0.005). The net reclassification index 
achieved by adding log (CACS + 1) and FRS was 0.551 
Table 2 Univariate and multivariate predictors of cardiovascular events
ACE-I angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, NAFLD non-alcoholic fatty liver disease, LDL low-density lipoprotein, HDL-C high-
density lipoprotein, HbA1c glycated hemoglobin A1c, CACS coronary artery calcium score, FRS Framingham risk score, ESC European Society of Cardiology, DPP4 
dipeptidyl peptidase-4
Variables Univariate Multivariate
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age 1.04 (1.01–1.07) 0.010 1.00 (0.96–1.04) 0.938
Male, gender 1.64 (0.87–3.10) 0.127 2.50 (1.01–6.18) 0.047
Hypertension 1.28 (0.63–2.60) 0.496 0.77 (0.38–1.57) 0.467
Dyslipidemia 1.28 (0.69–2.36) 0.439 1.14 (0.59–2.22) 0.695
Current smoker 1.21 (0.61–2.39) 0.592 0.75 (0.35–1.62) 0.467
Obesity 1.12 (0.62–2.03) 0.704 0.96 (0.49–1.88) 0.912
β blocker 0.56 (0.22–1.43) 0.229
Calcium channel blocker 1.46 (0.82–2.67) 0.189
ACE-I or ARB 1.20 (0.66–2.17) 0.554
Statin 1.05 (0.58–1.90) 0.872
Insulin therapy 0.87 (0.44–1.73) 0.690
Oral antihyperglycemic drugs 0.81 (0.45–1.47) 0.488
Metformin 0.36 (0.13–1.00) 0.050
Thiazolidinediones 1.95 (0.90–4.19) 0.089
Alpha glucosidase inhibitor 0.50 (0.18–1.40) 0.189




NAFLD 2.91 (1.61–5.25) < 0.001 5.43 (2.82–10.44) < 0.001
Total cholesterol 1.00 (0.99–1.01) 0.934
LDL cholesterol 1.00 (0.99–1.01) 0.944
HDL cholesterol 0.99 (0.96–1.01) 0.151
Log (triglyceride) 1.48 (0.84–2.60) 0.178
HbA1c 0.93 (0.77–1.12) 0.424
Log (CACS + 1) 1.48 (1.27–1.72) < 0.001 1.56 (1.32–1.86) < 0.001
FRS 1.14 (1.05–1.24) 0.002 1.23 (1.08–1.39) 0.001
ESC very-high risk group 1.41 (0.72–2.73) 0.316
Page 7 of 10Ichikawa et al. Cardiovasc Diabetol            (2021) 20:8  
(p < 0.001). The addition of NAFLD to CACS and FRS 
thus improved the predictability of cardiovascular events.
Discussion
This study demonstrated that the presence of NAFLD in 
non-enhanced CT images, in addition to CACS and FRS, 
improved the risk classification of cardiovascular events 
in T2DM patients. However, this study was conducted 
in a cohort of T2DM patients with suspected coronary 
artery disease, and further studies are needed to deter-
mine if the results apply to all T2DM patients.
Several lines of evidence have shown that NAFLD is 
associated with an increased risk of cardiovascular events 
in T2DM patients. Lee et  al. showed that NAFLD was 
independently associated with progression of carotid 
intima-media thickness, as a well-established surrogate 
marker of subclinical atherosclerosis, in T2DM patients 
[21]. In an observational study of 2103 T2DM patients, 
NAFLD was associated with an increased incidence of 
cardiovascular events after adjustment for multiple risk 
factors (HR 1.96, 95% CI 1.4–2.7) [22]. However, the 
mechanisms by which NAFLD increases the risk of car-
diovascular events are complex and not fully understood. 
A previous study showed that the histological severity of 
NAFLD was associated with increased arterial stiffness 
and endothelial dysfunction [23]. In addition, inflamma-
tory cytokines increased in line with the severity of liver 
disease in NAFLD patients [24]. The presence of systemic 
inflammation promoted by cytokines secreted from the 
liver leads to endothelial dysfunction, altering vascu-
lar tone and enhancing vascular plaque formation. This 
mechanism was supported by a clinical study that found 
a significant association between the severity of NAFLD 
and both surrogate markers of atherosclerosis and an 
increased risk of cardiovascular mortality in NAFLD 
patients [25–28].
CACS is a well-established surrogate marker of sub-
clinical coronary artery atherosclerotic plaque burden, 
which can predict risk beyond the established cardio-
vascular risk score. Budoff et al. reported that CACS was 
independently and strongly associated with cardiovas-
cular events, and CACS > 100 signified at least a 7.5% 
10-year risk of cardiovascular events regardless of age, 
sex, or ethnicity among 6814 subjects from the general 
population [29]. CACS is also used to predict cardio-
vascular risk in T2DM patients, with elevated CACS in 
T2DM compared with non-T2DM subjects [30]. The 
Diabetes Heart Study comprising 1123 T2DM patients 
demonstrated that CACS predicted cardiovascular 
events more accurately than FRS [4]. In addition, the 
Fig. 3 Incremental prognostic value of NAFLD in addition to CACS and FRS. a Global χ2 test. b Receiver operating characteristic curve 
analysis. NAFLD non-alcoholic fatty liver disease, CACS coronary artery calcium score, FRS Framingham risk score
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2019 AHA/ACC guidelines for the primary prevention 
of atherosclerotic cardiovascular disease included the 
measurement of CACS for patients in intermediate-risk 
groups [6]. These data support the possible use of CACS 
as a means of assessing risk for cardiovascular outcomes 
in T2DM patients.
Hepatic steatosis has been reportedly associated with 
the presence of coronary artery calcium in some stud-
ies [31–33]. In addition, Sung et al. reported that hepatic 
steatosis was independently associated with coronary 
artery calcium progression [34]. However, the associa-
tion between NAFLD and CACS has been inconsistent 
across studies, especially in T2DM patients. In a study 
of 213 participants with T2DM, NAFLD was not asso-
ciated with CACS in patients with glycated hemoglobin 
A1c (HbA1c) < 7%, but was significantly associated with 
CACS in patients with HbA1c ≥ 7% [35]. In contrast, 
McKimme et  al. reported no significant association 
between hepatic steatosis and CACS in T2DM patients 
[36]. Kim et al. reported an association between NAFLD 
and the prevalence of CACS, but this association was 
attenuated and was no longer significant after adjust-
ing for insulin resistance [37]. The current study also 
found no association between NAFLD and higher CACS. 
Given that our results indicated that NAFLD and CACS 
were independent factors, the combination of NAFLD 
and CACS might improve the identification of T2DM 
patients at higher risk of cardiovascular events.
Ultrasonography is commonly used to assess liver fat 
infiltration in clinical practice; however, non-enhanced 
CT can also be useful for diagnosing liver fat. Previous 
studies showed that a liver:spleen ratio < 1.0 could be 
used effectively to diagnose the presence of liver fat with 
high reproducibility [18, 38, 39]. However, the preva-
lence of NAFLD in T2DM in this study was lower than 
that reported in other studies [40], in which NAFLD was 
mostly diagnosed by ultrasonography and magnetic res-
onance imaging. On the other hand however, our study 
applied CT, which was reported to have a lower sensitiv-
ity for diagnosing hepatic steatosis compared with ultra-
sonography and magnetic resonance imaging, especially 
in cases with mild steatosis (< 30% steatosis) [41]. The 
present study may thus have included patients with mod-
erate to severe hepatic steatosis.
NAFLD is closely associated with obesity [22], and the 
prevalence of NAFLD has been reported to increase in 
parallel with increasing severity of obesity [42]. Recently, 
severe obesity among children and adolescents has 
recently become a significant public health concern [43]. 
Furthermore, pediatric fatty liver disease clustered with 
cardiometabolic risk factors, associated with an increase 
in subsequent adult cardiovascular mortality among ado-
lescents with severe obesity [44]. A healthier diet and 
physical activity should thus be promoted among adoles-
cents with obesity to mitigate the cardiometabolic risk.
This study had several limitations that need to be 
addressed. First, the number of patients and cardiovas-
cular events were relatively small. In addition, our study 
population only consisted of Japanese patients with sus-
pected coronary artery disease, and the results therefore 
cannot be applied directly to the T2DM population or to 
other ethnic groups. Second, the histological severity of 
liver damage was not confirmed in this study. However, 
CT is a useful tool for diagnosing NAFLD, without the 
complications associated with invasive methods. The 
association between CACS and histologic findings of 
NAFLD, such as ballooning grade, need to be evaluated 
in future studies. Third, we have no data about the dura-
tion of T2DM, which has been reported to increase the 
risk of cardiovascular events [45]. Fourth, longitudinal 
information on changes in medications, risk factor con-
trol, and changes in body mass index and lifestyle during 
the follow-up period was not available. Finally, FRS was 
originally developed in Western societies and is therefore 
not accurate in Asians. The Suita score has been pro-
posed and validated as an alternative score for predict-
ing coronary heart disease in Japanese populations [46]. 
The application of the Suita score instead of FRS did not 
affect the findings of this study (data not shown).
Conclusions
This study demonstrated the potential incremental prog-
nostic value of NAFLD assessed by non-enhanced CT, 
in addition to CACS, for risk stratification of cardiovas-
cular events in T2DM patients with suspected coronary 
artery disease. Further studies are needed to validate the 
applicability of NAFLD and CACS examination by non-
enhanced CT to all T2DM patients.
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